Abiomed touts positive results for its Symphony heart pump
Abiomed unveils clinical updates on its Symphony device following the 2nd successful human use in Canada, showing positive results over 28 days.
Massachusetts medical device company Abiomed (NSDQ:ABMD) reported positive clinical results for the 1st Canadian patients implanted with the company's Symphony device, a minimally invasive pump designed to slow the progression of heart failure and help the heart remodel.
A pair of patients received the Symphony implant in September and showed an improvement over 28 days in hemodynamics and physical functionality based on support via a "pacemaker-like" implantation technique, the company said. The trial was performed by Dr. Renzo Cecere at McGill University Health Centre in Montreal, Quebec.